111 related articles for article (PubMed ID: 23334725)
1. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
Heuveling DA; de Bree R; Vugts DJ; Huisman MC; Giovannoni L; Hoekstra OS; Leemans CR; Neri D; van Dongen GA
J Nucl Med; 2013 Mar; 54(3):397-401. PubMed ID: 23334725
[TBL] [Abstract][Full Text] [Related]
2. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
4. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
5. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
[TBL] [Abstract][Full Text] [Related]
7. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.
Beer AJ; Grosu AL; Carlsen J; Kolk A; Sarbia M; Stangier I; Watzlowik P; Wester HJ; Haubner R; Schwaiger M
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6610-6. PubMed ID: 18006761
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.
Schechter NR; Wendt RE; Yang DJ; Azhdarinia A; Erwin WD; Stachowiak AM; Broemeling LD; Kim EE; Cox JD; Podoloff DA; Ang KK
J Nucl Med; 2004 Oct; 45(10):1683-7. PubMed ID: 15471833
[TBL] [Abstract][Full Text] [Related]
9. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
10. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
[TBL] [Abstract][Full Text] [Related]
11. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
13. Imaging tumor perfusion and oxidative metabolism in patients with head-and-neck cancer using 1- [11C]-acetate PET during radiotherapy: preliminary results.
Sun A; Johansson S; Turesson I; Daşu A; Sörensen J
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):554-60. PubMed ID: 21236601
[TBL] [Abstract][Full Text] [Related]
14. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.
Lehtiö K; Oikonen V; Grönroos T; Eskola O; Kalliokoski K; Bergman J; Solin O; Grénman R; Nuutila P; Minn H
J Nucl Med; 2001 Nov; 42(11):1643-52. PubMed ID: 11696633
[TBL] [Abstract][Full Text] [Related]
15. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
16. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
17. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
[TBL] [Abstract][Full Text] [Related]
18. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
19. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.
Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M
Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465
[TBL] [Abstract][Full Text] [Related]
20. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
